Healthcare News by GLG Council Members

Critical thinking and creativity in AD research

November 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:New Treatment Halts Progress of Alzheimer's Disease | www.abdn.ac.uk

The recetn  clinical results suggest that plaque removal is not enough to halt progressive neurodegeneration in Alzheimer Disease and prompt some intriguing challenges to the amyloid hypothesis.

Health Tourism in Ghana a reality or a dream?

November 8, 2009

Analysis by: GLG Expert Contributor

Analysis of:Ghana targets health tourism boom | news.bbc.co.uk

Due to the increasing costs or health care in the U.S and the perception that health care is cheaper in other countries, even with the travel and housing expenses, patients are succumbing to the foreign markets.India, Indonesia and other countries, with lower costs of labor and less expenses overall are getting into the market of delivering surgical services such as cardiac and cosmetic surgery at bargain prices.The question is this really a bargain and what are the real issues?

Ken PowellPresidentGenesis Business Development, LLC

What's Next for Sequenom?

November 7, 2009

Analysis of:So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com

Those following the Sequenom saga continue their seemingly endless attempts to decipher a clear direction for the company.  Amid data mishandling, executive terminations and a stunning $300 million dollar lawsuit, there could be options for the company to revive and survive.

Novartis, Sleeping Giant Wakes-Up in China

November 6, 2009

Analysis by: GLG Expert Contributor

Analysis of:Novartis to invest US$ 1 bn to build largest pharma R&D institute in China | www.pharmabiz.com

Novartis to grow its China presence, late.Novartis has a slow response to market opportunities.GlaxoSmithKline and other big pharma players are perhaps too large to compete in the world's changing markets.

Is GE Global Research Developing a Portable Solar-Powered Ultrasound Device?

November 6, 2009

Analysis by: GLG Expert Contributor

Analysis of:GE Global Research bags US$ 1.2 mn NIH project for developing technology in prenatal care | www.pharmabiz.com

As the recipient of a new NIH grant, GE Healthcare should create and design new innovative features as a way to differentiate its products in the nascent point-of-care portable ultrasound marketplace.  Reasons why GE Healthcare should pursue a risk-taking strategy, such as developing a portable solar-powered ultrasound device and background information supportive of this strategy is offered in the following analysis.        

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC)

Potential impact of large clinical trial on Liquid based cytology market

November 5, 2009

Analysis of:Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com

The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology has essentially replaced conventional Pat testing in this country, and it is unlikely that there is evidence that would reverse this. However, it is possible such studies will put downward pricing pressures on reimbursments, both in amounts and frequencies.

Ken PowellPresidentGenesis Business Development, LLC

FDA Publishes H1N1 Diagnostic Test Guidance

November 5, 2009

Analysis of:FDA Publishes Guidance Document for H1N1 Dx | www.genomeweb.com

The FDA published document designed to help diagnostic test manufactures develop H1N1 tests and data that would accompany a FDA application to market them.  This follows on the recent issuance of CDC guidelines for H1N1 tests.

Ken PowellPresidentGenesis Business Development, LLC

Genomic Health Posts a 41% Q3 Revenue Increase

November 5, 2009

Analysis of:Genomic Health Posts 41 Percent Revenue Increase for Q3 | www.genomeweb.com

Genomic Health (NASDAQ: GHDX) posted Q3 revenues that were 41% greater than Q3 08.  Virtually all of the revenue out performance was due to sales of the company's Oncotype Dx molecular diagnostic test for breast cancer used in developing a therapeutic strategy and assessing risk of recurrence.

Should we use 3D imaging for “routine orthodontic cases”?

November 4, 2009

Analysis by: GLG Expert Contributor

Analysis of:Should we use 3D imaging for “routine orthodontic cases”? | www.pcsortho.org

When 3D imaging became available for practitioners in Orthodontics, Oral Surgery and Dentistry, the question most often asked is: "Does 3D imaging really make any difference in my treatment planning and treatment of my patients?" The information gained with 3D imaging is obvious, but does it really make any difference, especially in 'routine cases'?

Ken PowellPresidentGenesis Business Development, LLC

Court Denies Lawsuit Dismissal Motion by Myriad Genetics and Others

November 4, 2009

Analysis of:Court Denies Motion to Dismiss BRCA Patent Suit Against Myriad, Others | www.genomeweb.com

The US District Court for the Southern District of New York denied a motion to dismiss the lawsuit brought against Myriad Genetics, the US Patent and Trademark Office and the University of Utah Research Foundation by the Association for Molecular Pathology, the American Civil Liberties Union and Public Patent Foundation at the Benjamin N. Cardozo School of Law, and others.  This outcome of this lawsuit will significantly impact the patent landscape and business models for companies engaging in genetic testing.

Previous Page : 12345678910Next21 to 30 of 7849